European stock markets closed mixed in Wednesday trading as fighting reignited in the Middle East and President Donald Trump saying Iran must "pay the price" for taking too long to close a peace deal.
The Stoxx Europe edged 0.1% higher, Germany's DAX fell 0.9%, the FTSE 100 rose 0.3%, France's CAC lost 0.3%, and the Swiss Market Index closed 0.7% higher.
Bank stocks closed lower in Wednesday trading with Societe Generale, and BNP Paribas falling 2.1% and 1.4%, respectively, in Paris, while Commerzbank dropped 2.2% in Frankfurt. HSBC and Standard Chartered lost 1.4% and 1.2%, respectively, in London, while UniCredit fell 1.2% in Milan.
Automotive stocks also declined, with Stellantis and Renault falling 3.8% and 1.6%, respectively, in Paris, while BMW and Porsche lost 1.3% and 1.2%, respectively, in Frankfurt. Shares of Volvo dropped 3.6% in Stockholm, while Ferrari's stock closed 1% lower in Milan.
In corporate news, shares of energy company EnQuest surged 30% in London trading after it said Wednesday that its EnQuest Petroleum Production Malaysia unit has agreed to acquire three separate packages that include interests in four offshore production sharing contracts in Malaysia.
The company said that acquisitions would constitute a reverse takeover for the purposes of the UK's Financial Conduct Authority's listing rules.
Flutter Entertainment's FanDuel Predicts unit said Wednesday that it has signed an expanded event contract with Crypto.com's regulated trading platform OG Prediction Markets. Financial terms were not disclosed. The product expansion comes just before the World Cup begins.
Shares of the sports betting and gaming operator rose 5% in London.
French pharmaceutical company Sanofi said Wednesday that it will discontinue a phase 3 trial of its experimental drug riliprubart in patients with a type of chronic inflammatory demyelinating polyneuropathy after an interim review found the study was unlikely to provide sufficient efficacy.
The company said it will review the future of its other ongoing riliprubart studies, including a trial involving patients with the same condition who are being treated with intravenous immunoglobulin.
Shares of Sanofi declined close to 1% in Paris.